NEW YORK, NY / ACCESSWIRE / October 9, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Auris Medical Holding AG (NASDAQ: EARS), a company focused on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
EARS shares were up over 50% in intra-day trading on October 8th as an analyst initiated coverage with a "buy" rating and a price target far above the current price. Trading volume exceeded 15X the average daily volume.
Analysts-initiated coverage and target price READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/auris-medical-2/
Recently the company announced feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA) related to the development plan and regulatory pathway for AM-111, its investigational treatment for sudden sensorineural hearing loss. The Type C meeting had been requested by the Company following the results of the HEALOS phase 3 trial. In a written response the FDA endorsed the proposed choice of primary and secondary efficacy endpoints, the safety endpoints, as well as the planned sample size and statistical methodology. In addition, the FDA provided important guidance on the regulatory path forward.
A review of the company pipeline and financial data here READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/auris-medical-2/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: [email protected]
SOURCE: Traders News Source